Stocks · News reference

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Aug 12, 2026, 4:05 PMBenzinga Newsdesk

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 9:30 PMBenzinga Newsdesk
UPDATE: Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.70) by 14.29 percent. This is a 98.17 percent increase over losses of $(43.80) per share from
Read original at benzinga
VOR
BenzingaAug 11, 2026, 1:36 PMBenzinga Newsdesk
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.70) by 65.71 percent. This is a 99.54 percent increase over losses of $(251.24) per share from
Read original at benzinga
VOR
SEC EDGARJul 7, 2026, 8:04 PMSEC EDGAR
8-K filing — Vor Biopharma Inc. (VOR)
Filed: 2026-07-07 AccNo: 0001193125-26-297454 Size: 155 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgar
VOR